NVNO Stock Overview
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
enVVeno Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.23 |
| 52 Week High | US$6.97 |
| 52 Week Low | US$2.51 |
| Beta | 1.12 |
| 1 Month Change | -4.21% |
| 3 Month Change | 24.52% |
| 1 Year Change | 24.52% |
| 3 Year Change | -16.59% |
| 5 Year Change | -91.10% |
| Change since IPO | -96.01% |
Recent News & Updates
Recent updates
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
Mar 07
Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?
Aug 14Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?
Apr 22We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate
Dec 21enVVeno Medical: Unique Exposure To Venous Treatment Domain
Sep 23We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely
Aug 23enVVeno Medical reports Q2 results
Aug 03We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth
May 10We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate
Jan 25Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
Sep 08Hancock Jaffe Laboratories finance chief sheds interim tag
Dec 31Hancock Jaffe approves 1:25 reverse stock split
Nov 27Shareholder Returns
| NVNO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 9.4% | 1.8% | 1.2% |
| 1Y | 24.5% | -0.5% | 24.9% |
Return vs Industry: NVNO exceeded the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: NVNO matched the US Market which returned 24.9% over the past year.
Price Volatility
| NVNO volatility | |
|---|---|
| NVNO Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVNO's share price has been volatile over the past 3 months.
Volatility Over Time: NVNO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 31 | Robert Berman | www.envveno.com |
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company’s lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI.
enVVeno Medical Corporation Fundamentals Summary
| NVNO fundamental statistics | |
|---|---|
| Market cap | US$69.65m |
| Earnings (TTM) | -US$23.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs NVNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVNO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$23.52m |
| Earnings | -US$23.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NVNO perform over the long term?
See historical performance and comparison